AI assistant
Sending…
Kymera Therapeutics, Inc. — Director's Dealing 2021
Mar 16, 2021
31145_dirs_2021-03-16_262254ac-7107-44f7-a683-2f2e4cc7de08.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kymera Therapeutics, Inc. (KYMR)
CIK: 0001815442
Period of Report: 2021-03-12
Reporting Person: Ridloff Elena (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-12 | Stock Option (Right to Buy) | $56.10 | A | 40127 | Acquired | 2031-03-11 | Common Stock (40127) | Direct |
Footnotes
F1: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on March 12, 2021.
More from Kymera Therapeutics, Inc.
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Board/Management Information
2026
Mar 27
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 25
Regulatory Filings
2026
Mar 23
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4